CURRICULUM VITAE Walid L. Shaib, MD 1. Name: Walid L Shaib (Citizen) Cellphone: 404 450 9944 2. Office Address: The Hope Clinic 100 Market Place Blvd Ste 102 Cartersville, GA 3012 3. Office number/Fax: (678) 721-5555 E-mail Address: [email protected]; [email protected] 4. Current Titles and Affiliations: Medical Doctor (MD), Northwest Georgia Oncology Primary Appointments: Hematology/Medical Oncology at Northwest Georgia Oncology (NGOC) 2022 - present Academic Appointments: Associate Professor – Hematology/Medical Oncology and Gastrointestinal Medical Oncology Winship Cancer Institute of Emory University School of Medicine Atlanta, GA 30322, 2014 – 2022 5. Previous Academic and Professional Appointments: Chief Resident Department of Internal Medicine Yale New Haven Hospital – HSR Campus 20 York Street New Haven, CT 06510 2010 – 2011 7. Previous Administrative and/or Clinical Appointments: Revised: 7/9/2022 Chief Fellow, Hematology-Medical Oncology Winship Cancer Institute of Emory University School of Medicine Atlanta, GA 30322 2013 - 2014 8. Licensures/Boards: § USMLE Step 1, Issued 2006 § USMLE Step 2 CK, Issued 2006 § ECFMG Certification, Issued 2006 § USMLE Step 3, Issued 2007 § Connecticut Trainee Medical License, 2007 - 2009 § Connecticut Medical License, 2009 - 2011 § American Board of Internal Medicine, Issued 2011 § Georgia State Medical License, 2011- Present § American Board of Certification in Hematology, Issued 2014 § American Board of Certification in Medical Oncology Board, Issued 2014 9. Specialty Boards: • American Board of Internal Medicine, Board Certified, 2010 • American Board of Internal Medicine, Medical Oncology Diplomate, 2014 • American Board of Internal Medicine, Hematology Diplomate, 2014 10. Education: • BA, Biology, American University of Beirut, Beirut Lebanon 1998 - 2001 • MD, Medicine, American University of Beirut, Beirut Lebanon, 2001 – 2005 • JM, Juris Master concentration on health law, 2017 - 2021 11. Postgraduate Training: Post Graduate Year 1, Pediatrics prelim, American University of Beirut, Beirut, Lebanon, Supervisor: Mohammad Mikati, MD, Director, 2005 – 2006 Research Fellow, Children’s Cancer Center of Lebanon, St. Jude, Beirut, Supervisor: Miguel Abboud, MD, Director 2006 – 2007 Internal Medicine Residency, Yale New Haven Hospital, New Haven, Connecticut, Supervisor: Robert Nardino, MD, Director 2007 – 2010 Chief Resident, Internal Medicine, Yale New Haven Hospital, New Haven, Connecticut, Supervisor: Robert Nardino, MD, Director 2010 – 2011 Hematology/Oncology Fellow, Winship Cancer Institute of Emory University, Atlanta, Georgia Supervisor: Ruth O’Regan, MD 2011 – 2014 Revised: 7/9/2022 Chief Fellow, Winship Cancer Institute of Emory University, Atlanta, Georgia, Hematology/Oncology Supervisor: Ruth O’Regan, MD 2013 – 2014 12. Continuing Professional Development Activities: • Juris Master, Emory University, 2017 – 2021 13. Committee Memberships: a. National and International: 1. Eastern Cooperative Oncology Group (ECOG) American College of Radiology Imaging Network (ACRIN) 2013 – present 2. GI Committee Member, Hoosier Cancer Research Network (HCRN), 2014 - Present 3. Committee Member, Healing NET, 2017 – Present 4. Committee Member, Academic and Community Cancer Research United (ACCRU), 2018 - present 5. North American Neuroendocrine Tumor Society member (NANETS) 2018 - present 6. National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) (NRG- oncology), GI committee member 2018 – present 7. NRG oncology, Neuroendocrine Tumor Core committee member, 2019 – present 8. National Cancer Institute (NCI) Gastrointestinal Steering Committee Member representing NRG Oncology on the Neuroendocrine Tumors Task Force. 2019 – present 9. Neuroendocrine Tumor Research Foundation (NETRF) member 2019- present b. Institutional: 1. Committee Member, Hematology/Oncology Fellowship Selection Committee, Emory University, Atlanta, GA, 2014 – 2015 1. Committee Member, Phase I Solid Tumor Group, Emory University, Atlanta, GA 2014 – 2022 2. Committee Member, Institutional Review Board Committee, Emory University, Atlanta, GA, 2015 – 2022 4. Winship Grand rounds Director, Emory University, Atlanta, GA, 2020 – 2022 14. Peer Review Activities: a. Grants Institutional: 1. Genomics in Ampullary Cancers - Elkin Fellowship Award, 2013 – 2014 National Revised: 7/9/2022 2. Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award, 2017 – 2018 International 3. American Society of Clinical Oncology – Methods in Clinical Cancer Research Workshop Vail, Colorado- protocol Development, 2013 b. Manuscripts: 1. BioMedCancer,2013 2. ScientificReports,2015 3. Cancer,2016 4. CurrentMedicinalChemistry,2017 5. Cancers,2017 6. TheOncologist,2018 7. BMCCancer4/2019 8. JournalOfGeriatricOncology5/2019 9. Clinical Advances in Hematology and Oncology, 10/2019 10. JAMA Oncology 05/2021 15. Consultantships/Advisory Boards: 1. Advisory Board Member, Arqule, 2017 2. Advisory Board Member, Ipsen, 2018 3. Advisory Board Member, BluePrintsMedicine,2019 4. Advisory BoardMember, BristolMyerSquibb, 2020 5. Advisory Board Member,Lexicon, 2020 6. Advisory Board Member, Exelexis 2020 7. Advisory Board Member, Bayer, 2020 16. Honors and Awards: 1. American University of Beirut – Dean’s List, 1998 – 1999 2. Yale New Haven Hospital – Excellence in Teaching Contribution, 2008 – 2009 3. Yale New Haven Education and Research – President’s Award, 2010 – 2011 4. American Society of Clinical Oncology – Methods in Clinical Cancer Research Workshop Vail, Colorado- protocol Development, 2013 5. Genomics in Ampullary Cancers - Elkin Fellowship Award, 2013 – 2014 6. Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award, 2017 – 2018 17. Society Memberships: 1. American College of Physicians – (ACP), 2007 – 2011 2. American College of Physicians - (ACP) Connecticut Chapter, 2010 – 2011 3. American Society of Clinical Oncology (ASCO), 2011 – Present 4. American Society of Hematology (ASH), 2012 – 2014 5. American Association for Cancer Research (AACR), 2013 – 2016 Revised: 7/9/2022 6. Eastern Cooperative Oncology Group (ECOG) American College of Radiology Imaging Network (ACRIN) 2013 – 2022 7. HOOSIER Cancer Research Network (HCRN)- Gastrointestinal (GI) committee member, 2014 - 2022 8. NRG Oncology, 2018 – 2022 9. North American Neuroendocrine Tumor Society (NANETS) member, 2018 - 2022 10. National Cancer Institute (NCI) Gastrointestinal Steering Committee Member for Neuroendocrine Tumors Task Force. 2019 – 2022 11. Neuroendocrine Tumor Research Foundation (NETRF) member 2019- 2022 12. Annual Meeting Scientific Program Committee - Gastrointestinal Cancer - Colorectal and Anal. ASCO 2020 to 2023 13. Mentor for the 2020-22 ASCO Virtual Mentoring Program (VMP) 14. ASCO Abstract reviewer for 2021 and 2022 meeting- Colorectal committee 2020-2022 18. Organization of Conferences: a. Institutional: Administrative Positions: • Course director of the 8th Annual Winship Gastrointestinal Cancer Symposium at Emory University, 2018 • Director of the Neuroendocrine Symposium at Emory University, 3/2019 • Course director of the 9th Annual Winship Gastrointestinal Cancer Symposium at Emory University, 2019 • Moderator of the Colorectal Cancer session in the 9th Annual Winship Gastrointestinal Cancer Symposium at Emory University, 2019 • Moderator of the Colorectal Cancer session in the 9th Annual Winship Gastrointestinal Cancer Symposium at Emory University, 2020-2021 • Sessions as Chair: • Colorectal Cancer session in the 9th Annual Winship Gastrointestinal Cancer Symposium at Emory University, 2019 • Neuroendocrine tumor session in the 10th Annual Winship Gastrointestinal Cancer Symposium at Emory University, 2020 • ASCO GI poster session on Colorectal Cancer, 2022 • NANETS Pancreatic NET session, 2022 19. Clinical Service Contributions: • Ethics Committee member for Yale New Haven Hospital 2010 – 2011 • Chief Internal Medicine Resident, Yale New Haven Hospital 2010 – 2011 • Acute Sickle Cell Center at Grady Memorial Hospital 2012 – 2014 • Chief Fellow for Hematology and Oncology Program at Emory University 2013 - 2014 • Clinical Specialist at the Veterans Affairs Emergency Room. 2012- 2014 Revised: 7/9/2022 • Infusion Center Physician Coverage 2014- present • Phase I physician 2014- present • Clinic Committees – Meeting every week to discuss challenges in GI oncology clinics and how to improve practice and system 2014 – 2022 • Grady outpatient and inpatient coverage • Reviewer of Quality Improvement for Concurrent Chemoradiation, Grady Memorial Hospital, 2015 – 2017 • Institutional Review Board at Emory University: Meeting monthly to review clinical trials and address ethical issues related to each trial. 2016 – 2022 • National Co-PI and study champion, NRG Oncology clinical trial: EA2142: Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and WellDifferentiated Neuroendocrine Neoplasms 2018- present • I lead the Peptide Radionuclide Receptor Therapy (PRRT) program from the medical oncology side along with Dr Schuster from nuclear medicine side for the Neuroendocrine tumors at Emory University. 2018 – 2022 20. Community Outreach: a. General: 1- Neuroendocrine Tumor Support Group for Patients in Georgia, 2016 – Present 2- Pancreas Cancer Support Group Meetings with Patients, 2017 – Present 3- Healing NET patient advocacy meeting, 2017 – present 4- Neuroendocrine Symposium presentation for patients, 2019 5- Healing NET, Nursing Education meeting, 2019 6- HOSA judge 2019, HOSA Conference on March 14th, Public Service Announcement and Health Career Display sessions 21. Formal Teaching: a. Medical Student Teaching: • Preceptorship - Clinical Assessment and Problem-Solving Course, Yale University School of Medicine, New Haven, CT (100 hours annually) 2010 – 2011 • Lecturer - Lymph Node Assessment, Internal Medicine Residents, Emory University, Atlanta, GA (1 hour) 2014 • Manuscripts with medical students, teaching medical writing (2015 – present) • Teaching medical Student as part of the Discovery program at Emory University A) Layal Sayegh- Pancreatic Cancer project (published at Pancreas journal)- 2017 - 2018 B) Mohammad Basel Allaw- Neuroendocrine Tumor project, 2019 – 2020 • Dr Katerina Zakka. Research fellow. Teaching on medical writing and working on several manuscripts on analysis of the National Cancer DataBase (NCDB) • Observership for international medical students (Drs Patrick Samra- 2015, Jean-Pierre Nammour-2016, Dany Debs – 2017, Christelle Dagher- 2018 and Diala Merheb-2019) Revised: 7/9/2022 • Supervisory teaching, Field Supervisor for Rollins School of Public Health: Teaching PhD students for data analysis with Dr Zhengjia Chen and helped with their practicum. 2 students. b. Graduate Programs: Residency Programs: • Huang, Weixing (2018) • Dr Tian Feng (2019) • Lecturer: Advances in Neuroendocrine Tumor, Radiology Department at Emory University, Atlanta, GA, 2017 (1 hour) • Lecturer: Gastrointestinal Malignancies Board Review, Internal Medicine, Emory University, Atlanta, GA, 2018 (1 hour) • Lecturer: Integrating new Therapies into Treatment Regimens for Gastric and Gastroesophageal Cancer – Union Hospital, Indianapolis, IN 2018 (1 hour) • Lecturer: New Modalities in Treatment of Pancreatic Cancer, Balamand University, Beirut, Lebanon, 2018 (1 hour) i. Fellowship Programs: • Lecturer: Gastro-Esophageal Cancers, Hematology/Oncology Fellows, Emory University, 2013 (1 hour) • Lecture: Advanced Colorectal Cancer, Hematology/Oncology Fellows, Emory University, 2014 (1 hour) • Lecturer: Hepatobiliary Cancers, hematology/Oncology Fellows, Emory University, 2015 (1 hour) • Moderator: Board Review in Gastrointestinal Cancers, Hematology/Oncology Fellow, Emory University, 2016 (1 hour) • Lecturer: Rare GI Malignancies, Hematology/Oncology Fellows, Emory University, 2016 (1 hour) • Lecturer: Pancreatic Cancer, Hematology/Oncology Fellows, Emory University, 2017 (1 hour) • Moderator: Board Review in Gastrointestinal Cancers, Hematology Fellows, Emory University, 2017 (1 hour) • Lecturer: Rare GI Malignancies, Hematology/Oncology Fellows, Emory University, 2018 (1 hour) • Board Review in Gastrointestinal Cancers, Hematology Fellows, Emory University, 2019 (1 hour) • Lecturer: Neuroendocrine Tumors; Hematology/Oncology Fellows, Emory University, 2020 (1 hour) • Lecturer: Neuroendocrine Tumors; Hematology/Oncology Fellows, Emory University, 2021 (1 hour) 22. Supervisory Teaching: a. Postdoctoral Fellows Directly Supervised: • Hematology/Oncology Fellow Supervision in GI Oncology Ambulatory Clinic, 2014 – 2020 Revised: 7/9/2022 • Rita Assi, MD, Assistant Professor, 2015 American University of Beirut, Beirut Lebanon • Mukesh Kumar, MD, 2015, Amos Cancer Center, Columbus, GA • Ghada Kunter,MD, 2015, Northwest GA Oncology Centers, P.C. Jasper Cancer Center, Jasper, GA • Olatunji B Alese, MD, 2015 Assistant Professor, Emory University, Atlanta, GA • James Qu Fellow, MD, 2016, Virginia Commonwealth University, Richmond, VA • Hiromi Terawaki, MD, 2016, Cancer Care of Western North Carolina, Ashville Oncology, Ashville, NC • Andrew lp, MD, 2016, Hematology/Oncology Fellow, Emory University • Deepak Ravindranathan, MD, MS, Hematology/Oncology Fellow, Emory University 2020 • Basel Nazha, MD, MS, Hematology/Oncology Fellow, Emory University 2020 • Christopher Williamson, PGY1 (10/2020) • Lavanya Dharmarajan, MD, PGY-1 • Deepthi Kodali, MD Hematology/ Oncology Fellow PGY-4 • Dylan Baker, MBBS Emory Internal Medicine PGY3 b. Other: 1. Patrick Samra, 2014, Medical Student from the American University of Beirut 2. Hussein Assi, 2014, Internal Medicine Resident from the American University of Beirut 3. Samantha Shams, Internal Medicine Resident, (2014 – 2015), Emory University 4. Paul Gill, 2015, Internal Medicine Resident from Emory University 5. James Qu, 2015, Internal Medicine Resident from Emory University 6. Loraine Calfur, 2015, Fellow in Hematology and Oncology, Emory University 7. Dany Debs, 2016, Medical Student from the Balamand University, Beirut, Lebanon 8. Samantha Alonso, 2016, Internal Medicine Resident from Emory University Rita Assi, MD, Assistant Professor, (2016), American University of Beirut, Lebanon 9. Anna Pinheiro, Medical Student, (2016 –2018), Emory University, Atlanta, GA 10. Jean Pier Nammour, Fellow in Hematology Oncology, (2016), Balamand University, Balamand Al Kurah, Lebanon 11. Sonali Kumar, MD, 2016, Internal Medicine Resident from Emory University 12. Andrew Ip, 2017, Fellow in Hematology and Oncology, Emory University 13. Kamal Kucuk, 2017, Medical Student, Turkey University of Sciences 14. Sherri Bogard, MD, PGY1 Resident, 2017, Internal Medicine Resident from Emory University 15. Rajasree Roy, MD, PGY2 Emory Resident, 2017, Internal Medicine Resident from Emory University 16. Elizabeth Sakach, MD, PGY, 1 Resident, 2017, Internal Medicine Resident from Emory University 17. Sanjay Handrasekaran, MD, 2017, Internal Medicine Resident from Emory University 18. Becca Engels, MD, MPH, 2017, Internal Medicine Resident from Emory University 19. Evan K Brady, MD, 3rd year Internal Medicine, 2017, Internal Medicine Resident from Emory University 20. John Haydek, MD, 2017, Internal Medicine Resident from Emory University 21. Srinivasa Nithin Gopalsamy, 2017, Internal Medicine Resident from Emory University 22. Michael Corban, 2017, Internal Medicine Resident from Emory University Revised: 7/9/2022 23. Amrita Karambelkar, MD Resident, 2017, Internal Medicine Resident from Emory 24. Brianna McDaniels, Student, (2018), Genetics Counseling, Emory University 25. Amit Surya Narayan, Internal Medicine Resident, (2018), Emory University, Atlanta, GA 26. Christelle Dagher, MD, (2018), Research Fellow, American University of Beirut, Lebanon 27. Layal Sayegh, MD, Internal Medicine Resident, (Yr) Emory University, Atlanta, GA (2018) 28. Craig Cook, MD PGY-1, 2018, Internal Medicine Resident from Emory University 29. Chelsea E. Modlin, MD, PGY-1, 2018, Internal Medicine Resident from Emory University 30. Christelle Dagher, Medical Student, 2018, Balamand University, Beirut, Lebanon 31. David L. Minkoff, 2018, Internal Medicine Resident from Emory University 32. Vladimir Lamm, MD, PGY 1, 2018, Internal Medicine Resident from Emory University 33. Nancy Thakkar, MD, PGY, 2018, Internal Medicine Resident from Emory University 34. Mangaladevi Patil, MD, PGY 1, 2018, Internal Medicine Resident from Emory University 35. Meghana Anugu, PGY-1, 2018, Internal Medicine Resident from Emory University 36. Chris Haydek, MD, PGY, 2018, Internal Medicine Resident from Emory University 37. Jennifer Xu, PGY2, 2019, Internal Medicine Resident from Emory University 38. Hamdi, Sherif, PGY-1 2019, Internal Medicine Resident from Emory University 39. Deepak Ravindranathan, MD, MS, Hematology/Oncology Fellow, Emory University 2020 40. Basel Nazha, MD, MS, Hematology/Oncology Fellow, Emory University 2020 41. Dylan Baker, MBBS Emory Internal Medicine PGY3 (10/2020) 42. Christopher Williamson PGY1 rad/onc (10/2020) 43. Omid Behbahani-Nejad, MD, MS Emory Internal Medicine, PGY-1 (3/2021) 44. Alex Matelski, MD , PGY-1 | Emory University School of Medicine (2/2021 & 4/2021) 45. Lana Khalil, MD research fellow at Emory University (01/2021-present) 23. Lectureships, Seminar Invitations ,and Visiting Professorships: a. National and International: • Evidence-based Management of Advanced Gastric Cancer and Gastroesophageal Junction Cancers, Hematology and Oncology, Roswell Park, NY, 2018 • Integrating New Therapies into Treatment Regimens for Gastric and Gastroesophageal Cancer’, Raliegh County Medical Society, West VA, 2018 • New Modalities of Treatment in Pancreatic Cancer’, Lebanese Society of Medical Oncology, Beirut, Lebanon, 2018 • Healing NET, Nashville, TN ‘Directions and Dead Ends: The Promising and the Less Promising’ April 6, 2019 • ASCO chairing Colorectal cancer session 2022 • NANETS chairing pancreatic NET session 2022 b. Regional: 1. Adjuvant Treatment in Cholangiocarcinoma’, Invited Speaker – Winship 2. Cancer Institute GI Symposium, Atlanta, GA 2015 Revised: 7/9/2022 3. First Line Treatment of Colon Cancer: EGFR or VEGF Target?, Invited Speaker – Debates and Didactics, Sea Island, GA 2016 Role of Cytotoxic Treatments in NET’, Invited Speaker - North American Neuroendocrine Tumor Society, Atlanta, GA 2016 1. Advances in Gastric Cancer, Invited Speaker – Debates and Didactics, Sea Island, GA 2016 2. Targeted Therapy for GIST, Invited Speaker – Winship Cancer Institute, GI Symposium, Atlanta, GA 2017 3. Treatment of GIST (Gastro-Intestinal Stromal Tumors), Wellstar Healthcare System, Atlanta, GA, 2018 4. Targeted and Immune Therapies for Hepatocellular Carcinoma, Invited Speaker – Debates and Didactics, Sea Island, GA 2018 5. Adjuvant therapy for Colon Cancer, Invited Speaker – Winship Cancer Institute (WCI) GI Symposium, Atlanta, GA 2018 6. Management of Carcinoid Syndrome, Speaker, Neuroendocrine Tumors (NET) Symposium, Atlanta GA, 2019 7. Role of Peptide receptor radionuclide therapy (PRRT) in treatment of NET, Debates and Didactics, Sea Island, GA 2019 8. Winship Grand rounds Pancreatic cancer updates. Atlanta, GA. 07/2020 c. Institutional: 1. Rare Gastrointestinal Cancers, Speaker – WCI, Hematology/Oncology Fellows, Atlanta, GA, 2014 – 2016 2. Neuroendrocrine Tumors – Emory University, Atlanta, GA 2016 3. Updates in Locally Advanced Rectal Cancer – Emory University, Atlanta, GA 2016 4. Updates in Pancreatic Cancers – Grand Rounds, Emory University, Atlanta, GA 2018 5. Grand Rounds at Emory University on Treatment Modalities in Pancreatic Cancer. Atlanta, GA 2020 24. Invitations to National/International, Regional, and Institutional Conferences: a. Regional: 1. Updates on GIST Management Wellstar GI Symposium, Atlanta, GA 2018 2. GI symposium 2018 December 14,2018 on Updates on Cholangiocarcinoma 3. Panel moderator for GI colorectal cancer session in GI symposium 09/2019 at Emory University Debates and Didactics, Sea Island July 25, 2019 on Neuroendocrine Tumor treatment updates. 4. Grand Round at Emory University on Pancreatic Cancer Treatment Update. 7/2020 5. NRG concept presentation on Ramucirumab/Everolimus for treatment of NET in 2nd and 3rd line. 8/2020 6. NCI presentation of the Ramucirumab/Everolimus for treatment of NET in 2nd and 3rd line. 9/2020 7. GI Symposium 8th, 2/2021. Debate on PRRT versus Targeted therapy in second line NET treatment Revised: 7/9/2022 25. Abstract Presentations at National/ International, Regional, and Institutional Conferences: a. National and International: 1. ‘Vitamin A Induced Hepatotoxicity,’ (poster) *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October, 2008 2. ‘Pericardial Effusion in a Primary Hypothyroid Patient with Medication Non-adherence’, (poster) *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2009 3. ‘Black Esophagus’, (poster) Samir Samarany, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2009 4. ‘Severe Clostridium difficile Colitis Associated with Adriamycin and Cyclophosphamide’ (poster) T. Ayach, MD, C. Tabiri, MD, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 5. ‘Iatrogenic Cushing Syndrome Casued by HAART and Fluticasone’, (poster) Youmna Lahoud, MD, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 6. ‘Primary Spinal Cord Lymphoma in a Young Immunocompetent Patient’ (poster) Jad Kebbe, Olivia-Pop Fabiola, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 7. ‘Hypercalcemia Related to Acute T-Cell Lymphoma: An Unknown Mechanism’ (poster) Rosette Kfoury, MD, Mehmet Altan, MD, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 8. ‘A Case of Idiopathic Retroperitoneal Fibrosis’ (poster) Mehmet Altan, MD, Paul Fiedler, MD, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 9. ‘Choking from Prostate Cancer!’ (poster) Sara Emami, *Walid L Shaib, Samuel Bobrow, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 10. ‘Late Onset myasthenia Gravis : A Challenging Presentation Leading To Acute Respiratory Failure’ (poster) Elie T, Nader, MD, *Walid L Shaib, ACP Connecticut Chapter Meeting, Hartford, CT, October 2010 11. Appendiceal Cancer: Mutational profile Revealed By Next Generation Sequencing’ (poster) Daniel A Goldstein MD, *Walid L Shaib, Michael Rossi, Volkan Adsay, Charles Staley, MD, Philip J Stephens, Bassel F El-Rayes,. GI ASCO, June 2015, San Francisco, Ca, USA 12. ‘Management and Outcomes of Hospitalized Patients with primary Neuroendocrine Tumor (NET) and Non-Net Appendiceal Cancers in the United States’, (poster) Olatunji B Alese, MD, Sungjin Kim, Zhengjia Chen, *Walid L Shaib, Edith Brutcher, NP, Ganji Purnachandra Nagaraju, Patrick S. Sullivan, Charles A Staley, Suresh S. Ramalingam, MD, Taofeek K Owonikoko Bassel F. El-Rayes 13. Comprehensive Genomic Profiling of Cancer of the Appendix to Reveal New Routes to Targeted Therapies’ (poster) Daniel A. Goldstein, Julia Andrea Elvin, Kai Wang, *Walid L Shaib, Michael R Rossi, Philip j. Stephens, Jeffrey S. Ross, Bassel F El-Rayes, MD, J Clin Oncol 33, 2015 (suppl 3; abstr608) GI ASCO 2015, San Francisco, Ca, USA 14. BBI608-118 (BBI608-201PANC): A PHASE Ib Extension study of Cancer Stemness Inhibitor Napabucasin (BBI-608) in Combination with Nab-Paclitaxel (nab-PTX) and Revised: 7/9/2022 Gemcitabiine in Patients (pts) with Metastatic pancreatic (oral presentatiion) Bassel ElRayes, MD, S Shahda, MD, O’Neil Starodub BH, MD, *Walid L Shaib, MD, C Oh, MD,W Li, MD, YZ Li, MD, L Borodyansky, MD, CJ Li, MD and T Bekaii-Saab, MD J Clin Oncol 34, 2016, ASCO 2016, (suppl 4S; abstract 196) 15. ARQ 087, an oral pan- Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) V. Mazzaferro, Walid L Shaib, L. Rimassa, W. Harris B. El-Rayes, A. W. Tolcher, T. Hall, Y. Wang, B. Schwartz, J. Kazakin, M. Droz Dit Busset, C. Cotsoglou, K.P. Papadopoulos ESMO GI 2016, Barcelona, Spain 16. ‘Resection of Pancreatic Cancer Following Induction Chemotherapy’ *Walid L Shaib, MD, ASCO GI 2018 San Francisco, Ca, USA 17. Phase Ib Trial of Pembrolizumab and XL888 in Patients with Advanced Gastrointestinal Malignancies (poster) Mehmet Akce, MD Olatunji B Alese, MD, *Walid L Shaib, Christina Sing-Ying Wu, Grebory B Lesinski, Bassel F El-Rayes, MD, ASCO GI 2018, San Francisco, Ca, USA 18. A phase II Study of Pembrolizumab in Combination with mfolfox6 FOR Patients with Advanced Colorectal Cancer. Safi Shahda, Anne M. Noonan, Tanios S Bekaii-Saab, Bert H. O’Neil, MD, Amikar Sehdev*Walid L Shaib,MD; Bassel El-Rayes, MD, (Poster) Journal of Clinical Oncology 35, no.15_suppl (May 2017) 3541-3541. ASCO 2017 Chicago, Il, USA 19. In Driven Tumors, Preclinical Pharmacokinetics (PK) Pharmacodynamics (PD) and Efficacy Translate into Clinical Activity of ARQ 087, *Walid L Shaib – (Poster) ASCO 2017 , Chicago, Il, USA 20. A Phase Ib/2 Study of Cancer Stemness Inhibitor Napabucasin (BBI-608) in Combination with Gemcitabine (GEM) & nab-Paclitaxel (nabPTX) in Metastatic Pancreatic Adenocarcinoma (mPDAC) patients (pts), *Walid L Shaib– (Poster) ASCO 2017, Chicago, Il, USA 21. Racial Disparities in Treatment and Outcomes of Young Adults with Colorectal Cancer, Olatunji Alese, MD; *Walid L Shaib, (Poster) AMERICAN SOCIEITY OF CLINICAL ONCOLOGY 2017, Chicago, Il, USA 22. Combining Ganetespib Plus Carfilzomib impairs Metabolic homeostasis Leading to Cell Death in Human Pancreatic Cancer Cells, *Walid L Shaib (Poster) AMERICAN SOCIEITY OF CLINICAL ONCOLOGY 2017, Chicago, Il, USA 23. Phase I Study of Ganetespib (G), Capecitabine © and Radiation ® in Rectal Cancer (NCT01554969), *Walid L Shaib (Poster) AMERICAN SOCIEITY OF CLINICAL ONCOLOGY 2017, Chicago, Il, USA 24. Epidemiology and Treatment of High-Grade Gastrointestinal Neurondrocrine Tumors (HG-GI-NETs). Olantunji B Alese, MD, Renjian Jiang, *Walid L Shaib, MD, Christina Sing-Ying Wu, MD, Mehmet Akce, MD, Madhusmita Behera, Bassel F. El-Rayes, MD; Gastrointestinal Cancer Symposium, San Francisco, CA, GI AMERICAN SOCIEITY OF CLINICAL ONCOLOGY (poster) J Clin Oncol 36, 2018 (suppl 4S; abstract 421) San Francisco, Ca, USA 25. Altering the Cytokine Profile in the Pancreatic Cancer Microenvironment with Heat Shock Protein-90 Inhibitors to Enhanced immunotherapy. ASCO 2018 Abstract ID: 618 Program number: 58.7 (VAC.1256) Walid Shaib, Bassel El-Rayes, Chicago, Il, USA Revised: 7/9/2022 26. Blood Based Biomarkers and Clinical Outcome in Advanced Stage Cancer Patients (pts) Treated with Immunotherapy (IO) Dylan J. Martini, Yuan Liu, Collen Lewis, Hannah Collins, Mehmet Akce, Haydn Kissick, Bradley C. Carthon, MD, *Walid L Shaib, MD Olatunji B. Alese, Rathi Pillai, MD, Conor E. Steuer, Christina Wu, MD, David H. Lawson, Ragini Kudchadkar, Bassel El-Rayes, Viraj A. Master, Suresh Ramalingam, Taofeek K. Owonikoko, R. Donald Harvey, Mehmet Asim Bilen: AACR 2018 , Atlanta, GA, USA 27. Phase 1b/2 Trial of Cancer Stemness Inhibitor Napabucasin (NAPA) + nab-Paclitaxel (nPTX) and Gemcitabine (Gem) in Metastatic Pancreatic Adenocarcinoma (mPDAC) – (Poster) Tanios Bekaii-Saab, Alexander Starodub, Bassel El-Rayes, Safi Shahda, Bert O’Neil, MD, Anne Noonan, *Walid L Shaib, Wahid Hanna, Sameh Mikhail, Anterpreet Neki, Yue Chang, Xiaoshu Dai, Wei Li, Emily Brooks, Cindy Oh, Laura Borodyansky, and Chiang J. Li; ASCO 2018- Chicago, Il, USA 28. Adjuvant Treatment for Resected Sub-Centimeter T1 Pancreatic Cancer, *Walid L Shaib, MD – (Poster) AMERICAN SOCIEITY OF CLINICAL ONCOLOGY 2018 (4125) 29. A Phase I/II Study of Trifluridine/Tipiracil (TAS-102) in Combination with Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers, *Walid L Shaib, MD, (Poster) ASCO 2018 TPS4155, Chicago, Il, USA 30. Incidence, Treatment and Survival Outcomes of Small Bowel Adenocarcinomas, Mehmet Akce, Renjian Jiang, Christina Wu, Olatunji B Alese, Walid L Shaib, Madhusmita Behera, Bassel El-Rayes, GI ASCO 2018, San Francisco, Ca, USA 31. Role of Adjuvant Therapy in Resected State IA Sub-Centimeter (T1aT1b) Pacreatic Cancer, Walid L Shaib, Amit Surya Narayan, Jeffrey M. Switchenko, PhD, Sujata Kane, NP, Christina Wu, MD, Mehmet Akce, Olatunji B. Alese, Pretesh Patel, Shishir K Maithel, Juan Sarmiento, David Kooby, Bassel F El-Rayes, American Society of Clinical Oncology, Chicago, IL 2018 (Poster) Abstract Number for Publication: 4125 32. Blood-based next-generation sequencing analysis of neuroendocrine *Walid L Shaib JCO.2019.37.15_suppl.4110 Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 4110-4110. Poster Board: 215 Abstract Number: 4110 (Poster) ASCO 2019, Chicago, Il, USA 33. Radiation as a single modality treatment in localized pancreatic cancer. Walid L Shaib, Katerina Mary Zakka, Asser Shahin, Fares Yared, Jeffrey M. Switchenko, Christina Wu, Mehmet Akce, Olatunji B. Alese, Pretesh R. Patel, Mark William McDonald, Bassel F. El-Rayes. Journal of Clinical Oncology Abstract 703, GI ASCO 2020, San Francisco, CA, USA 34. Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma. Walid L Shaib, Katerina Mary Zakka, Jeffrey M. Switchenko, Christina Wu, Mehmet Akce, Olatunji B. Alese, Pretesh R. Patel, Mark William McDonald, Bassel F. El-Rayes. ASCO 2020, abstract # 4583. Virtual Meeting 35. Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer. Mehmet Akce, Manali Rupji, Jeffrey M. Switchenko, Walid L Shaib, Christina Wu, Olatunji B. Alese, Maria Diab, Gregory B. Lesinski, Bassel F. El-Rayes JCO.2021.39.3_suppl.95 Journal of Clinical Oncology 39, no. 3_suppl (January 20, 2021) 95-95. 36. Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas. Maria Diab, Jeffrey M. Switchenko, Christina Wu, Mehmet Akce, Olatunji B. Alese, Bassel F. ElRayes, Walid L Shaib. Journal of Clinical Oncology ASCO 2021 abstract # 341041 Revised: 7/9/2022 37. Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma. Walid L Shaib. 2021 Cholangiocarcinoma Foundation Annual Conference Poster presentation (04/2021) 38. A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers. Wen Wee Ma, Tyler J. Zemla, Daniel Walden, Robert R. McWilliams, Walid L Shaib, Daniel H. Ahn, Bassel F. ElRayes, Thorvardur Ragnar Halfdanarson, Timothy J. Hobday, Sarah Bruggeman, Brandy L. Jaszewski, Fang-Shu Ou, Christina Wu, Tanios S. Bekaii-Saab Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 563-563. GI ASCO – San Franscisco 2022 39. Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Lana Khalil, Sandra Kang, Ashley McCookVeal, Amber Draper, Maria Diab, Walid Labib Shaib, Olatunji B. Alese, Bassel F. ElRayes, Mehmet Akce Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 4118-4118. GI ASCO – San Franscisco 2022 40. Telotristat ethyl with PRRT in the treatment of well differentiated neuroendocrine tumors Tony Z. Zhuang, Saima Muzahir, Kristina D. Murphy, Mehmet Akce, Olatunji B. Alese, Maria Diab, Olumide B. Gbolahan, Walid L Shaib. ASCO Chicago, USA. 2022 26. Research Focus I lead as an investigator a randomized, double blinded, placebo controlled, multi-institutional trial comparing FOLFIRINOX to FOLFIRINOX/Ramucirumab in metastatic pancreatic cancer. I also have another investigator-initiated trial using Telotristat combined to chemotherapy for pancreatic cancer patient who had lost 10% of their weight. I was awarded a grant from the Hirshberg Foundation for Pancreatic Cancer Research to explore the immune modulatory effects on pancreatic cancer tissue. I submitted a grant to test 5HTserotonin receptor expression on pancreatic cancer tissue. I am leading a multi-institutional study on cholangiocarcinoma that is molecularly driven by homologous recombinant deficiencies in the maintenance setting using Niraparib and Dostarlimab combination. I had initiated the PRRT program at Emory University, the second largest PRRT program for neuroendocrine tumors in the USA. I participated in phase I studies where I helped in the development of FGFR2 fusion target, Derazantinib, in cholangiocarcinoma. 27. Grant Support: Support ARQ087-101 Shaib (PI) 04/17/15-04/17/21. 433,413 $ A Phase I/II Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors The aim of the trial was to show safety of ARQ-087 at a dose of 300 mg po daily. This was on the escalation phase of the phase I trial which initially was a 3+3 dose escalation design. The drug was used in tumors that had any FGF or FGFR aberrations. Role: PI Revised: 7/9/2022 HCRN GI14-198 Shaib (PI) 08/05/16-08/05/22. 76,756$ Hoosier Cancer Research Network Phase II Randomized, Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients (Hoosier Cancer Research Network GI14-198) This study aims at testing the progression free survival between pancreatic cancer patients receiving standard of care FOLFIRINOX compared to FOLFIRINOX in combination with ramucirumab (study arm). It is a phase II randomized, double blinded, multi-institution trial. I am leading the trial and it is investigator-initiated trial. Role: PI (Investigator Initiated Trial funded through Eli Lilly) Multi-institutional ARQ 087-301 Shaib (PI) 06/15/17-06/15/27. 252,691$ A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma This is a phase I trial of 3+3 design with an expansion cohort (ARQ 101) for intrahepatic cholangiocarcinoma patients carrying the FGFR2 gene fusion. I was the principal site investigator with the highest accrual. This study has now moved to a single arm phase 2 (ARQ 301) where we are still accruing patients on. Role: PI EA2142 – Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas 8/2/2019 – 8/1/2021 Aims: Evaluating the effect of 2 chemotherapy regimens (pick the winner) on high grade stage IV neuroendocrine patients. I am the study champion through the NRG. Role: Study Champion for an NCTN trial. WINSHIP4441-18 Shaib (PI). 3/6/2019 – 3/7/2029. 250,000$ Weight Loss in Patients with Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl Role: PI This is an investigator initiated trial targeting weight loss in pancreatic cancer which is a very important target. Weight loss is proportional to cachexia and stabilizing weight exposes patients to further chemotherapy hopefully leading to improved overall survival. HCRN GI19-414 Shaib (PI) 06/03/2021-02/20/24. 1,400,000 $ Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma. Role: PI Revised: 7/9/2022 This is an investigator-initiated trial targeting homologous recombinant deficiency pathways in the maintenance setting in the treatment of advanced stage cholangiocarcinoma. b. Previous Support: 1. E2211 Shaib (PI) 10/1/2015 – 09/30/2016 A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). This trial aims at answering the question if Temozolomide is non- inferior to Temozolamide/capecitabine combination for patients with metastatic pancreatic neuroendocrine tumors. The primary endpoint was progression free survival. This trial is an ECOG –ACRIN multi-institutional trial. Role: PI 2. INCB 18424-267 Shaib (PI) 03/04/15-03/04/21. 69,580$ A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination with Regorafenib in Subjects with Relapsed or Refractory Metastatic Colorectal Cancer. The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer. 2014- 2015 Role: PI 3. MK3475-061 Shaib (PI) 09/02/15-09/02/21. 25,807$ Study of Pembrolizumab (MK-3475) Plus Chemotherapy versus Placebo Plus Chemotherapy in Participants with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) The goal of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. Role: PI 4. BBI-DSP7888-101(1007670) Shaib (PI) 09/10/15-09/10/21. 114,784$ Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients with Advanced Malignancies. This is a phase I trial of 3+3 design with dose escalation for a vaccine that targets WNT pathway in pancreatic cancer and MDS. This trial is at dose level 3 now and has closed accrual for the pancreas cancer cohort. Role: PI 5. I4T-MC-JVCU Shaib (PI) 07/16/15-07/16/21. 25,807$ A Study of Ramucirumab (LY3009806) in Combination with Capecitabine and Cisplatin in Participants with Stomach Cancer (RAINFALL) The trial aims at evaluating 5FU cisplatin ramucirumab first line treatment in metastatic gastric and Revised: 7/9/2022 gastroesophageal adenocarcinoma patients as compared to standard of care 5FU/cisplatin. This trial was presented at ASCO GI 2018 and did not show any difference in survival when adding ramucirumab to the standard of care 5FU cisplatin combination. Role: PI 6. ARQ NIS-001 Shaib (PI) 03/16/16-03/16/22. 31,937$ Molecular Analysis of Oncogenes in Tumor Samples from Adult Patients with Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma: Closed to accrual March 2018. This is a tissue analysis study for evaluating FGFR2 gene mutation in intrahepatic Cholangiocarcinoma samples. I helped identifying patients and sending tissues to Arqule for Analysis. Role: PI 1. CanStem111P Shaib (PI) 08/23/17-08/22/17. 129,243$ A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma. This is a phase III trial randomizing patients with pancreatic adenocarcinoma to standard of care gemcitabine/abraxane and combination of gemcitabine/abraxane/BBI. The main goal of this study is to assess overall survival of patients in each arm and compare the treatment trial arm (involving BBI608) to standard of care chemotherapy. Role: PI 2. WINSHIP3388-17 Shaib (PI) 02/21/17-02/2018. 40,000$ Hisrchberg Pancreatic Cancer Foundation Grant: Effect of Treatment on Immune Pathways in Pancreas Adenocarcinoma: A Tissue Comparative Study Aims: Neoadjuvant therapy (FOLFIRINOX followed by SBRT) modulates immune pathways in the tumor microenvironment in PDAC that can serve as therapeutic targets. To test this hypothesis, we will use banked surgical resection specimens from patients with PDAC. The patients will be in three groups: no neoadjuvant therapy (control), prior therapy with FOLFIRINOX or prior therapy with FOLFIRINOX followed by SBRT. Role: PI 3. UMCC 2017.026 / CA209-9FC Shaib (PI) 02/21/18-02/20/28. 69,480$ A Multi-Center Randomized Phase II Study of Nivolumab in Combination with Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer. The main goal of this study is to evaluate efficacy of treatment combinations and determine the PFS rate at 6 months in patients with advanced BTC treated with nivolumab, gemcitabine and cisplatin, or nivolumab and ipilimumab 28. Bibliography: a. Published and Accepted Research Articles (clinical, basic science, other) in Refereed Revised: 7/9/2022 Journals: 1. Walid L Shaib, Lansigan F, Cornfeld D, Syrigos K, Saif MW. Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP. 2008 Nov 3;9(6):708-14. 2. Walid L Shaib, Lee V, Saif MW. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. In Vivo. 2009 Sep-Oct; 23(5):821-6. 3. Golden M, Walid L Shaib, Havill N. Variable daptomycin susceptibility in patients receiving intravenous vancomycin for meticillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents. 2010 Mar; 35(3):306-8. 4. Saif MW, Kaley K, Lamb L, Pecerillo J, Hotchkiss S, Steven L, Brennan M, Penney R, Gillespie C, Walid L Shaib. Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. JOP. 2010 Mar 5;11(2):176-82. 5. Walid L Shaib, Mitchell K, Saif MW.Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. Yale J Biol Med. 2010 Mar;83(1):27-33. 6. Purvey S, Hanna M, Walid L Shaib, Saif MW. A case of Down syndrome who developed pancreatic cancer: a case report and review of literature. JOP. 2010 May 5; 11(3):285-7. 7. Saif MW, Larson H, Kaley K, Walid L Shaib. Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin Drug Saif. 2010 Jul 27. 8. Walid L Shaib; Deng Y; Zilterman D; Lundberg B; Saif MW. Assessing Risk and Mortality of Venous Thromboembolism in Pancreatic Cancer Patients Anticancer Res. 2010 Oct;30(10):4261-4. 9. Altan M; Usmani A; Angelo S, Fiedler P, MD; Walid L Shaib. A Case of Idiopathic Retroperitoneal Fibrosis Case Report Conn Med. 2011 Nov-Dec;75(10):607-12 10. Ashar Usmani; Samir Samarany; Robert Nardino; Walid L Shaib. Black Esophagus in a Patient with Diabetic Ketoacidosis - Case Report Conn Med. 2011 Sep;75(8):467-8 11. Walid L Shaib; Marina Mosunjac ; Alton B Farris III; Bassel El Rayes. Hepatoid Adenocarcinoma of the Lung: A Case Report and Review of literature J Gastrointest Cancer.2014 Dec;45 Suppl 1:99-102. 12. Walid L Shaib; Rahul Sharma, MD; Sungjin Kim; Nelson Chen; Shishir Maithel, MD; David Kooby MD; John Kauh, MD; Bassel El-Rayes, MD Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. J Surg Oncol. 2014 May;109(6):556-60. 13. Walid L Shaib, Martin LK, Choi M, Chen Z, Krishna K, Kim S, Brutcher E, Staley C 3rd, Maithel SK, Philip P, Abdel-Misih S, Bekaii-Saab TS, El-Rayes BF. Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. Oncologist. 2015 Aug;20(8):907-14. 14. Walid L Shaib, Krishna K, Kim S, Goodman M, Rock J, Chen Z, Brutcher E, Staley CI, Maithel SK, Abdel-Missih S, El-Rayes BF, Bekaii-Saab T. Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. Cancer Res Treat. 2015 Jun 5 Revised: 7/9/2022 15. Walid L Shaib, Goodman M, Chen Z, Kim S, Brutcher E, Bekaii-Saab T, El-Rayes BF .Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. Am J Clin Oncol. 2015 Aug 11. 16. Goldstein DA, Walid L Shaib, Flowers CXR. Cost and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park). 2015;29:175-83. 17.Nagaraju GP, Mezina A, Walid L Shaib, Landry J, El-Rayes BF. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Eur J Cancer. 2016 Jan;52:109-19. doi: 10.1016/j.ejca.2015.10.057. 18. Rajitha B, Belalcazar A, Nagaraju GP, Walid L Shaib, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF. Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. Cancer Lett. 2016 Apr 10;373(2):227- 33. 19. Michelle D Reid, Olca Basturk, Walid L Shaib, Serdar Balci1, Hye-Jeong Choi, Gizem Akkas, Bahar Memis, Brian S Robinson, Bassel F El-Rayes, Charles A Stales, Christopher A Staley, Joshua H Winer, Maria C Russell, Jessica H Knight,Michael Goodman, Alyssa M Krasinskas and Volkan Adsay. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases Modern Pathology (2016), 1–11 20. Walid L Shaib, MD; Natalyn Hawk; Richard Cassidy; Chao Zhang; David Kooby; Juan Sarmiento; Shishir K Maithel; Zghenia Chen; Edith Brutcher; Jerome Landry; Bassel El-Rayes. A Phase I Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer following modified FOLFIRINOX (NCT01446458) Int J Radiat Oncol Biol Phys. 2016 21. Xue Y, Vanoli A, Balci S, Reid MM, Saka B, Bagci P, Memis B, Choi H, Ohike N, Tajiri T, Muraki T, Quigley B, El-Rayes BF, Walid L Shaib, Kooby D, Sarmiento J, Maithel SK, Knight JH, Goodman M, Krasinskas AM, Adsay V. Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. Mod Pathol. 2016 Oct 14. doi: 10.1038/modpathol.2016.174 22. Pinheiro AP, Pocock RH, Dixon MD, Walid L Shaib, Ramalingam SS, Pentz RD. Using Metaphors to Explain Molecular Testing to Cancer Patients. Oncologist. 2017 Apr;22(4):445-449 23. Pinheiro APM, Pocock RH, Switchenko JM, Dixon MD, Walid L Shaib, Ramalingam SS, Pentz RD. Discussing molecular testing in oncology care: Comparing patient and physician information preferences. Cancer. 2017 May 1;123(9):1610-1616 24. Belalcazar A, Walid L Shaib, Farren MR, Zhang C, Chen Z, Yang L, Lesinski GB, El-Rayes BF, Nagaraju GP. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cellsCancer. 2017 Dec 15;123(24):4924-4933. doi: 10.1002 Revised: 7/9/2022 25. Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Walid L Shaib. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours Br J Cancer. 2017 Nov 21;117(11):1592-1599 26. Walid L Shaib, Jones JS, Goodman M, Sarmiento JM, Maithel SK, Cardona K, Kane S, Wu C, Alese OB, El-Rayes BF. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A SEER-Medicare analysis Oncologist. 2018 Feb 14. pii: theoncologist.2017-0487. 27. Kim HS, Walid L Shaib,* Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF. Phase Ib study of Pasireotide (P), Everolimus (E) and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases. (WCI20331 -NCT01469572)- Cancer. 2018 May 1;124(9):1992-2000. doi: 10. 1002. *SHARED PRIMARY AUTHORSHIP EQUAL CONTRIBUTION 28. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Walid L Shaib. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019 Jan;120(2):165-171. 29. Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Walid L Shaib, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, ElRayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17. 30. Walid L Shaib, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer. 2019 Jan 1;125(1):57-67. doi: 10.1002/cncr.31787. Epub 2018 Nov 20. 31. Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Walid L Shaib, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Invest New Drugs. 2019 Feb 6. 32. Alese OB, Jiang R, Walid L Shaib, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2018 Nov 27. pii: theoncologist.2018-0382. 33. Akce M, Jiang R, Alese OB, Walid L Shaib, Wu C, Behera M, El-Rayes BF. Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare Revised: 7/9/2022 clinical entities: a National Cancer Database (NCDB) analysis. J Gastrointest Oncol. 2019 Feb;10(1):85-94. 34. Nagaraju GP, Zakka KM, Landry JC, Walid L Shaib, Lesinski GB, El-Rayes BF. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Int J Cancer. 2019 Sep 15;145(6):1529-1537 35. McDaniels BA, Hianik RS, Bellcross C, Walid L Shaib, Switchenko J, Dixon MD, Meisel JL, Gogineni K, Pentz RD. The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology. J Cancer Educ. 2019 May 7 36. Walid L Shaib, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF. Induction Therapy in Localized Pancreatic Cancer. Pancreas. 2019 Aug;48(7):913-919. 37. Alese OB, Jiang R, Zakka KM, Wu C, Walid L Shaib, Akce M, Behera M, El-Rayes BF. Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. Cancer Epidemiol. 2019 Oct 7;63:101618 38. Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Walid L Shaib, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, ElRayes B, Ramalingam SS, Owonikoko TK, Harvey RD. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019 Aug 29;19(1):857. doi: 10.1186/s12885-019-6073-7. 39. Zakka K, Jiang R, Alese OB, Walid L Shaib, Wu C, Wedd JP, Sellers MT, Behera M, ElRayes BF, Akce M. Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma. J Hepatocell Carcinoma. 2019 Jul 22;6:119-12 40. Sahin IH, Akce M, Alese O, Walid L Shaib, Lesinski GB, El-Rayes B, Wu C. Akce M, Jiang R, Zakka K, Wu C, Alese OB, Behera M, El-Rayes BF. Clinical Outcomes of Small Bowel Adenocarcinoma. Clin Colorectal Cancer. 2019 41. Walid L Shaib, Zakka K, Hoodbhoy FN, Belalcazar A, Kim S, Cardona K, Russell MC, Maithel SK, Sarmiento JM, Wu C, Akce M, Alese OB, El-Rayes BF. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy.J Geriatr Oncol. 2019 Nov 6. 42. Akce M, Zakka K, Penley M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. J Surg Oncol. 2019 Nov 28. 43. Walid L Shaib, Zakka K, Staley C 3rd, Roberts A, Akce M, Wu C, Alese OB, El-Rayes BF. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. Oncologist. 2019 Nov 29. pii: theoncologist.2019-0558. Revised: 7/9/2022 44. Farren MR, Sayegh L, Ware MB, Chen HR, Gong J, Liang Y, Krasinskas A, Maithel SK, Zaidi M, Sarmiento JM, Kooby D, Patel P, El-Rayes B, Walid L Shaib*, Lesinski GB. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI Insight. 2020 Jan 16;5(1). * Shared Last Authorship and Correspondence 45. Owonikoko TK, Harvey RD, Carthon B, Chen Z, Lewis C, Collins H, Zhang C, Lawson DH, Alese OB, Bilen MA, Sica GL, Steuer CE, Walid L Shaib, Wu C, Harris WB, Akce M, Kudchagkar RR, El-Rayes BF, Lonial S, Ramalingam SS, Khuri FR. A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clin Cancer Res. 2020 Jan 31. 46. Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, Lewis C, Collins H, Akce M, Kissick HT, Carthon BC, Walid L Shaib, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA, Bilen MA. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer. 2020 Feb 1;126(3):575-582. 47. Alese OB, Jiang R, Walid L Shaib, Wu C, Akce M, Gaines T, Ni L, Behera M, El-Rayes BF. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes.Pancreas. 2020 Mar;49(3):341-354. 48. Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, Khan AI, Speak A, Lewis C, Collins H, Kissick HT, Carthon BC, Akce M, Walid L Shaib, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.Oncologist. 2020 Mar;25(3):e528- e535. 49. Walid L Shaib, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, Mcdonald M, El-Rayes BF. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas. 2020 Jul;49(6):822-829. 50. Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Walid L Shaib. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget. 2020 May 12;11(19):1749-1757. 51. Hianik RS, Campbell GP, Abernethy E, Lewis C, Wu CS, Akce M, Dixon MD, Walid L Shaib, Pentz RD. Provider Recommendations for Phase I Clinical Trials Within a Shared Decision- Making Model in Phase I Cancer Clinical Trial Discussions. JCO Oncol Pract. 2020 May 19:JOP1900772 52. Alese OB, Jiang R, Walid L Shaib, Wu C, Akce M, Behera M, El-Rayes BF High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2020 May;25(5):e877. Revised: 7/9/2022 53.Dabrowiecki A, Sankhla T, Shinn K, Bercu ZL, Ermentrout M,Walid L Shaib, Cardona K, Newsome J, Kokabi N. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases. Cardiovasc Intervent Radiol. 2020 Jul;43(7):1006-1014. 54. Owonikoko TK, Harvey RD, Carthon B, Chen Z, Lewis C, Collins H, Zhang C, Lawson DH, Alese OB, Bilen MA, Sica GL, Steuer CE, Walid L Shaib, Wu C, Harris WB, Akce M, Kudchagkar RR, El-Rayes BF, Lonial S, Ramalingam SS, Khuri FR. A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clin Cancer Res. 2020 Jun 1;26(11):2497-2505. 55. Walid L Shaib, Zakka KM, Jiang R, Yan M, Alese OB, Akce M, Wu C, Behera M, El-Rayes BF. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer. 2020 Jul 22. 56.Dabrowiecki A, Sankhla T, Shinn K, Bercu ZL, Ermentrout M, Walid L Shaib, Cardona K, Newsome J, Kokabi N Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases. Cardiovasc Intervent Radiol. 2020 Jul;43(7):1006-1014. 2020 May 4. 57. Alese OB, Zakka K, Huo X, Jiang R Walid L Shaib, Akce M, Behera M, Sullivan P, Wu C, El- Rayes BF. Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. J Surg Oncol. 2021 Feb;123(2):596-605 58. Walid L Shaib, Zakka KM, Jiang R, Yan M, Alese OB, Akce M, Wu C, Behera M, El-Rayes BF. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer. 2020 Sep 15;126(18):4136-4147. 59. McDaniels BA, Hianik RS, Bellcross C, Walid L Shaib, Switchenko J, Dixon MD, Meisel JL, Gogineni K, Pentz RD. The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology. J Cancer Educ. 2020 Oct;35(5):864-870 60. Zakka K, Williamson S, Jiang R, Reid MD, Alese OB, Walid L Shaib, Wu C, Behera M, ElRayes BF, Akce M. Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix? Surg Oncol. 2021 Mar;36:120-129 61. Hianik RS, Campbell GP, Abernethy E, Lewis C, Wu CS, Akce M, Dixon MD, Walid L Shaib, Pentz RD. Provider Recommendations for Phase I Clinical Trials Within a Shared Decision- Making Model in Phase I Cancer Clinical Trial Discussions. JCO Oncol Pract. 2020 Sep;16(9):e859-e867. 62. Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB, Shaib W, Bilen MA, Lawson DH, Wu C, Steuer CE, El-Rayes BF, Khuri FR, Lonial S, Waller EK, Ramalingam SS, Owonikoko TK. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. Br J Cancer. 2020 Oct;123(8):1228-1234. Revised: 7/9/2022 63. Akce M, Liu Y, Zakka K, Martini DJ, Draper A, Alese OB, Walid L Shaib, Wu C, Wedd JP, Sellers MT, Bilen MA, El-Rayes BF Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. Am J Clin Oncol. 2021 Feb 1;44(2):74-81. 64. Spira A, Hansen AR, Harb WA, Curtis KK, Koga-Yamakawa E, Origuchi M, Li Z, Ertik B, Walid L Shaib. Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies. Target Oncol. 2021 May 3. 67. Akce M, Zakka K, Jiang R, Williamson S, Alese OB, Walid L Shaib, Wu C, Behera M, ElRayes BF Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. Front Oncol. 2021 Mar 30;11:592351. 68. Akce M, Zakka K, Penley M, Jiang R, Khalil L, Alese OB, Walid L Shaib, Wu C, Behera M, El- Rayes BF Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treat Res Commun. 2021;27:100329. 69. Walid L Shaib, Zakka K, Huang W, Chen Z, Alese OB, Wu C, Akce M, El-Rayes BF. Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. Pancreas. 2021 Apr 1;50(4):529-536 70. Hianik RS, Owonikoko T, Switchenko J, Dixon MD, Walid L Shaib, Pentz RD. Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials. Psychooncology. 2021 May 26. 71. Bryson E, Sakach E, Patel U, Watson M, Hall K, Draper A, Davis C, Goyal S, Alese O, Akce M, Walid L Shaib, El-Rayes B, Szabo S, Wu C. Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. Clin Colorectal Cancer. 2021 Mar 16:S1533-0028(20)30170- 72. Lana Khalil, MD, Gao, Xingyu, MPH, Jeffrey M Switchenko, PHD, Olatunji B. Alese, MD, Mehmet Akce, MD, Christina Wu, MD, Maria Diab, MD; Bassel F. El-Rayes, MD, Walid L Shaib, MD. Elderly Patients with Stage III Colon Cancer. 73. Mohamed A, Jiang R, Philip PA, Diab M, Behera M, Wu C, Alese O, Shaib WL, Gaines TM, Balch GG, El-Rayes BF, Akce M High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer..Front Oncol. 2021 Oct 25;11:755113. doi: 10.3389/fonc.2021.755113. 74. Shaib WL, Zakka K, Penley M, Jiang R, Akce M, Wu C, Maithel SK, Sarmiento JM, Kooby D, Behera M, Alese OB, El-Rayes BF Role of Resection of the Primary in Metastatic WellDifferentiated Neuroendocrine Tumors..Pancreas. 2021 Nov-Dec 01;50(10):1382-1391 75. Alese OB, Zhou W, Jiang R, Zakka K, Huang Z, Okoli C, Shaib WL, Akce M, Diab M, Wu C, El-Rayes BF Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.Front Oncol. 2021 Dec 9;11:728076. Revised: 7/9/2022 76. Alese OB, Zakka K, Huo X, Jiang R, Shaib WL, Akce M, Behera M, Sullivan P, Wu C, ElRayes BF Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes..J Surg Oncol. 2021 Feb;123(2):596-605. 77. Spira A, Hansen AR, Harb WA, Curtis KK, Koga-Yamakawa E, Origuchi M, Li Z, Ertik B, Shaib WL Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies. Target Oncol. 2021 Jul;16(4):461-469. doi: 10.1007/s11523-021- 00813-6. 78. Zakka K, Williamson S, Jiang R, Reid MD, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF, Akce M.Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix? Surg Oncol. 2021 Mar;36:120-129. 79. Akce M, Liu Y, Zakka K, Martini DJ, Draper A, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, Bilen MA, El-Rayes BF Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. .Am J Clin Oncol. 2021 Feb 1;44(2):74-81. 80. Hianik RS, Owonikoko T, Switchenko J, Dixon MD, Shaib WL, Pentz RD Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials. Psychooncology. 2021 Oct;30(10):1739-1744. 81. Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB.A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother. 2021 Nov;70(11):3337-3348. 82. Allaw MB, Switchenko JM, Khalil L, Wu C, Alese OB, Akce M, Draper A, Jones AT, ElRayes B, Shaib W.Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Oncology. 2022;100(3):131-139. 83. Khalil L, Gao X, Switchenko JM, Alese OB, Akce M, Wu C, Diab M, El-Rayes BF, Shaib WL. Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. Oncologist. 2022 Jun 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=shaib+W b. Manuscripts Submitted: 1. Retrospective study evaluating the safety of administering pegfilgrastim on the same day of Fluorouracil pump disconnect Amber Draper, Christina Wu, Bassel F El-Rayes, Olatunji B Alese, Mehmet Akce, Walid L Shaib. 2. Ocular Metastasis from Neuroendocrine Tumors: A Case Series. Walid L Shaib, MD; Kamal Kucuk, MD; Sarah Wheeler, PharmD; Chris Bergstrom, MD; Bassel El-Rayes, MD Revised: 7/9/2022 3. Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma. Walid L Shaib, Katerina Zakka, Olatunji B. Alese, Christina Wu, Mehmet Akce, Bassel F. El- Rayes, Zhengjia Chen, Weixing Huang. Submitted – (Accepted as a poster at Chicago, IL ASCO 2020) 4. Chemoradiation Compared to Radiation Therapy Alone for T1N0 Anal Squamous Cell Carcinoma. Walid L Shaib, Katerina Zakka, Olatunji B. Alese, Christina Wu, Mehmet Akce, Bassel F. El-Rayes. Submitted Review Articles: 1. Walid L Shaib, Kono S, Saba N. Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck. J Oncol. 2012;2012:521215. 2. Walid L Shaib, MD; R. Mahajan, MD; Bassel El-Rayes, MD. Markers of Resistance to AntiEGFR Therapy in ColoRectal Cancer, J Gastrointest Oncol. 2013 Sep;4(3):308-18. 3. Walid L Shaib, Daniel Goldstein, Bassel F. El-Rayes. Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress? Current Colorectal Cancer Reports December 2014, Volume 10, Issue 4, pp 477- 486 4. Walid L Shaib, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist. 2016 Feb;21(2):178-87. 5. Sullivan PS, Moreno C, Walid L Shaib. Management of Anorectal and Intra-abdominal Infections in the Neutropenic Cancer Patient. Curr Probl Cancer. 2015 Sep-Oct;39(5):274-86. 6. Walid L Shaib, Nammour JP, Gill H, Mody M, Saba NF. Future Prospects of Immune Survival Outcomes of Adjuvant Chemotherapy in Therapy in Esophageal Carcinoma. J Clin Med. 2016 Nov 14;5(11) (CNCR-21-0959) Walid L Shaib, May 2021 7. Walid L Shaib, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, BekaiiSaab T, El-Rayes BF. Appendiceal Mucinous Neoplasms: Diagnosis and Management. Oncologist. 2017 Jun 29. pii: theoncologist.2017-0081. 8. Walid L Shaib, El-Rayes, B.F. Derazantinib (ARQ087) for Intrahepatic Cholangiocarcinoma Treatment - Drugs of the Future -- Clarivate Analytics, Drugs Fut 2017, 42(11): 677 9. Sahin IH, Akce M, Alese O, Walid L Shaib, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019 Nov;121(10):809-818. 29. Symposium Contributions: 1. Presenter for Winship Neuroendocrine Tumor Symposium, 3/2014 2. Presenter for Winship Gastrointestinal Malignancy Symposium, 12/2015 3. Presenter for Winship Gastrointestinal Malignancy Symposium, 12/2016 4. Presenter for Winship Gastrointestinal Malignancy Symposium, 12/2017 5. Co-director Winship Gastrointestinal Malignancy Symposium, 12/2018 6. Co-director Winship Gastrointestinal Malignancy Symposium, 9/2019 7. Director of the 3rd Annual Winship NET Symposium- Atlanta, GA, 3/2019 8. Co-director Winship Gastrointestinal Malignancy Symposium, 3/2021 Revised: 7/9/2022 30. Book Chapters: 1. Walid LShaib; Bassel El-Rayes,MD. BarrettsEsophagus–Novapublisher2012- 2. Walid L Shaib, Daniel Goldstein, Venicus Ernani, Ken Cardona, Maria Russel Rare GI Malignancies. Nova publisher 2014 3. Walid L Shaib. Current Problems in Cancer: Febrile Neutropenia in Solid Malignancies. Elsiever publisher. 2015. 4. Walid L Shaib. Current and Emerging Therapies in Pancreatic Cancer? Molecularly Targeted Therapies in Pancreatic Cancer" Springer Publishing Company 2019 5. Walid L Shaib. Diagnosis and Staging of Colorectal Cancer,” and “Molecular Diagnostic Guidelines” to be included in Handbook of Gastrointestinal Malignancies: Evidence-based Treatment and Multidisciplinary Patient Care Springer Publishing Company 03/2019 6. Walid L Shaib, Basel Allaw. Hereditary Syndromes in Neuroendocrine Tumors. Springer Publishing Company 2020 31. Manuals, Videos, Computer Programs, and Other Teaching Aids: 1. January 2017. Video to academic institution promoting accrual for the HCRN trial (investigator-initiated trial) 2. Georgia NET Cancer group- informal lecture on symptom management 4/2018 3. March 2019. Live Facebook appearance promoting the NET symposium and answering questions for NET patients. This appearance for 20 minutes on Facebook reaching out to patients and answering live questions along with follow up questions. It was aimed at educating patient and the community and raise awareness on the neuroendocrine tumors. 4. March 2019. Live Facebook appearance promoting the NET symposium and answering questions for NET patients. This appearance for 20 minutes on Facebook reaching out to patients and answering live questions along with follow up questions. It was aimed at educating patient and the community and raise awareness on the neuroendocrine tumors. 5. April 2019. Tapestry Through Healing NET https://www.youtube.com/watch?v=fE2WPcK_JQY 6. May 2019: Reaching out to the community oncologist through the Onclive program on recent advances in NET treatments 7. Georgia NET Cancer group (Patient advocacy group for NET, 100 patients in the group) - informal lecture on disease progression 6/2019 8. Georgia NET Cancer group- informal lecture on PRRT treatment 8/2019 9. Georgia NET Cancer group- informal lecture on NET treatment 6/2020 32. Contributions Not Otherwise Noted: 1. Multiple choice question writing: The Oncologist CME Online https://cme.alphamedpress.org/a/27884P2CBorv 9/15/2017 2. Health Occupations Students of America (HOSA) Conference on March 14th and/or 15, 2019 Public Service Announcement and Health Career Display sessions 3. Commentary in Atlas Science 06/2019- How to improve outcome in patients with primary appendiceal mucinous cancer (https://atlasofscience.org/how-to-improve-outcome-inpatients-with-primary-appendiceal-mucinous-cancer/) Revised: 7/9/2022 4. I am currently co-editing a book on GastroEnterPancreatic Neuroendocrine Tumors with Dr Philip Philip. Springer, a part of Springer Nature, is the publishing company.